Document Detail


Systemic lupus erythematosus: an update on current pharmacotherapy and future directions.
MedLine Citation:
PMID:  23339281     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: In the last decade, the development of a number of potential drugs for lupus that target the pathogenesis of the disease at different levels has been witnessed. Despite a number of negative trials during this period, belimumab was recently approved for the treatment of adult seropositive lupus patients with mild-to-moderate disease activity.
AREAS COVERED: This review summarizes the results of the most recent drug trials in lupus and highlights the aspects that require further refinement and modification in order to facilitate positive results in new drug trials for lupus.
EXPERT OPINION: The success of a clinical trial depends on the efficacy of the study drug and its appropriate dosing. Several other factors play a major role in the success of trials, including the patient inclusion criteria, the choice of evidence-based study outcomes and endpoints and other aspects of study design that are described in this review.
Authors:
Zahi Touma; Murray B Urowitz; Dafna D Gladman
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-23
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  13     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-08     Completed Date:  2013-09-25     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  723-37     Citation Subset:  IM    
Affiliation:
University of Toronto, Institute of Medical Science, Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Clinical Trials as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Immunoconjugates / therapeutic use
Immunosuppressive Agents / therapeutic use
Lupus Erythematosus, Systemic / drug therapy*,  pathology,  psychology
Mycophenolic Acid / analogs & derivatives,  therapeutic use
Quality of Life
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/Immunoconjugates; 0/Immunosuppressive Agents; 0/epratuzumab; 0/rituximab; 24280-93-1/Mycophenolic Acid; 252662-47-8/monoclonal antibody IDEC131; 73B0K5S26A/belimumab; 7D0YB67S97/abatacept; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interconverting conformations of slipped-DNA junctions formed by trinucleotide repeats affect repair...
Next Document:  Rhodium-Catalyzed Enantioselective Hydrogenation of Oxime Acetates.